Skip to main content
Clinical Trials/NCT05325749
NCT05325749
Unknown
Not Applicable

Development of the Technology and Methodology for Generation of the Genetic Passport (Genetic Health Record) of Newborn and Application Thereof to Estimate the Mid and Low Penetrance Hereditary Disorders Frequencies in Russian Population and to Uncover Genetic Factors Determining Severe Monogenic Conditions

Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare1 site in 1 country7,000 target enrollmentJuly 10, 2021
ConditionsInfant, Newborn

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infant, Newborn
Sponsor
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Enrollment
7000
Locations
1
Primary Endpoint
Phenotype-associated variants
Last Updated
4 years ago

Overview

Brief Summary

The aim of the study is to obtain the initial experience of the inclusive genetic screening of newborn.

Two groups of newborns born in RCOGP will be enlisted to the study:

  1. newborns without developmental features having no variations according to an inherited diseases screening;
  2. newborns showing either phenotypic features or deviations according to MS screening.

The residual volume of the cord blood of all newborns form both groups will be collected and subjected to the whole exome sequencing. The sequencing data will be analyzed in "screening" mode for the first group while for the second group analysis will be performed taking the respective phenotype into account.

The study is planned to cover 7000 newborns in total.

Registry
clinicaltrials.gov
Start Date
July 10, 2021
End Date
December 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Infants born in the RCOGP, showing no development features and with no inherited diseases revealed by common screening
  • Informed consent signed by a newborn's representative

Exclusion Criteria

  • Parents refuse to participate
  • Parent(s) younger 18 years
  • Parent(s) unable to make decisions
  • The infant is older 30 d
  • Blood cannot be collected from the infant
  • Group 2 (newborns with phenotypic features)
  • Inclusion Criteria:
  • Infants showing either phenotypic features or deviations according to MS screening
  • Informed consent signed by a newborn's representative
  • Exclusion Criteria:

Outcomes

Primary Outcomes

Phenotype-associated variants

Time Frame: 2 weeks - 2 months

Pathogenic, likely pathogenic variants or variants of uncertain significance corresponding to the observed clinical conditions

Motivations for refuse to participate

Time Frame: 1 day

Questionnaire answers provided by families refused to enroll

Estimate the frequency of revealing patients carrying genotype associated with a monogenic disese.

Time Frame: 3-5 months

The manifestation of pathogenic or likely pathogenic variants leading to a monogenic disease presenting during early age. A genotype is considered having risk of developping a monogenic disease in case pathogenic or probably pathogenic variants are detected corresponding to the inheritance model.

Acceptance of advanced screening

Time Frame: 1 day

Questionnaire answers provided by families accepted screening for variants of low penetrance, no care available etc.

Secondary Outcomes

  • Oncological risk(1 day)
  • Cardiological risk(1 day)
  • Recessive carriers(1 day)

Study Sites (1)

Loading locations...

Similar Trials